Adenoviral vectors for gene transfer

Current Opinion in Biotechnology

Volumn 8, Issue 5, 1997, Pages 583-589

  Kovesdi, Imre ^a   Brough, Douglas E ^a   Bruder, Joseph T ^a   Wickham, Thomas J ^a  

^a GENVEC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; CELL LINE; CELLULAR IMMUNITY; EXPRESSION VECTOR; GENE TARGETING; GENE TRANSFER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENE; VIRUS ASSEMBLY; VIRUS RECOMBINANT;

ADENOVIRIDAE;

EID: 0030663073     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(97)80033-X     Document Type: Article

References (80)

1. Ginsberg HS (Ed): The adenoviruses. New York: Plenum Press; 1984.
2. Doefler W, Böshm P (Eds): The molecular repertoire of adenoviruses. Berlin: Springer-Verlag; 1995.
3. Shenk T: Group C adenoviruses as vectors for gene therapy. In Viral Vectors. Edited by Kaplitt MD, Loewy AD. London: Academic Press; 1995:43-54.
4. Crystal RG: Transfer of genes to humans: early lessons and obstacles to success. Science 1995, 270:404-410.
5. Russell SJ: Replicating vectors for gene therapy of cancer: risks, limitations and prospects. Eur J Cancer 1994, 30:1171-1176.
6. Smith RR, Huebner RJ, Rowe WP, Schatten WE, Thomas LB: Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956, 9:1211-1218.
7. Bischoff JR, Kim DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274:373-376. This paper describes the use of a mutant adenovirus that has preferential replication advantage in p53-deficient human tumor cells in viral oncolysis. These results raise the possibility that mutant adenoviruses and other modified vectors may have potential in treating certain human tumors. This paper exemplifies the potential that adenovirus vectors will have in novel therapeutic uses.
8. Barker DD, Berk AJ: Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987, 156:107-121.
9. Hehir KM, Armentano D, Cardoza LM, Choquette TL, Berthelette PB, Whitte GA, Couture LA, Everton MB, Keegan J, Martin JM et al.: Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. J Virol 1996, 70:8459-8467.
10. Krougliak V, Graham FL: Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther 1995, 6:1575-1586.
11. Yeh P, Dedieu JF, Orsini C, Vigne E, Denefle P, Perricaudet M: Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 1996, 70:559-565.
12. Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I: A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996, 70:6497-6501. This paper describes a vector/cell line system for complete functional complementation of E1/E4-vectors. These are the first multi-region complementing cell lines and vectors that maintain production yields at the high level of E1- vectors.
13. Gao GP, Yang YP, Wilson JM: Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996, 70:8934-8943. This study indicates that E1/E4-vectors may have advantages of safety and transgene persistence for liver-directed gene therapy.
14. Gorziglia MI, Kadan MJ, Yei S, Lim J, Lee GM, Luthra R, Trapnell BC: Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol 1996, 70:4173-4178.
15. Zhou HS, O'Neal W, Morral N, Beaudet AL: Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J Virol 1996, 70:7030-7038.
16. Langer SJ, Schaack J: 293 cell lines that inducibly express high levels of adenovirus type 5 precursor terminal protein. Virology 1996, 221:172-179.
17. Schaack J, Guo XL, Langer SJ: Characterization of a replication-incompetent adenovirus type 5 mutant deleted for the preterminal protein gene. Proc Natl Acad Sci USA 1996, 93:14686-14691.
18. Amalfitano A, Begy CR, Chamberlain JS: Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc Natl Acad Sci USA 1996, 93:3352-3356.
19. Amalfitano A, Chamberlain JS: Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Gene Ther 1997, 4:258-263.
20. Engelhardt JF, Litzky L, Wilson JM: Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther 1994, 5:1217-1229.
21. Engelhardt JF, Ye X, Doranz B, Wilson JM: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994, 91:6196-6200.
22. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM: Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994, 91:4407-4411.
23. Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM: Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Gene 1994, 7:362-369.
24. Ye XH, Robinson MB, Batshaw ML, Furth EE, Smith I, Wilson JM: Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. J Biol Chem 1996, 271:3639-3646.
25. Fang B, Wang H, Gordon G, Bellinger DA, Read MS, Brinkhous KM, Woo SL, Eisensmith RC: Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther 1996, 3:217-222.
26. Rice SA, Klessig DF: Isolation and analysis of adenovirus type 5 mutants containing deletions in the gene encoding the DNA-binding protein. J Virol 1985, 56:767-778.
27. Dedieu JF, Vigne E, Torrent C, Jullien C, Mahfouz I, Caillaud JM, Opolon P, Delaere P, Orsini C, Perricaudet M, Yeh P: Long-term gene delivery into the liver of immunocompetent mice with E1/E4-defective adenoviruses. J Virol 1997, 71:4626-4637. These results suggest that E1/E4-vectors have extended long-term persistence of viral DNA in the liver of lacZ transgenic mice. However, transient transgene expression was observed independent of the extent of the E4 deletion, suggesting that the choice of promoter may be critical to expression persistence.
28. Kaplan JM, Armentano D, Sparer TE, Wynn SG, Peterson PA, Wadsworth SC, Couture KK, Pennington SE, St George JA, Gooding LR, Smith AE: Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum Gene Ther 1997, 8:45-56. This study suggests that persistence of transgene expression is determined by multiple factors including the genomic structure of the vector, the host background, and immune responses.
29. Armentano D, Zabner J, Sacks C, Sookdeo CC, Smith MP, St George JA, Wadsworth SC, Smith AE, Gregory RJ: Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol 1997, 71:2408-2416. These results suggest that nonimmunological factors have a major influence on persistence of transgene expression. The choice of promoter is important for persistence of expression and some promoters are influenced by the context of the vector backbone.
30. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT: A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc Natl Acad Sci USA 1996, 93:5731-5736.
31. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL: A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996, 93:13565-13570. A prokaryotic Cre/lox P recombination system was used, generating adenovirus vectors that lack all coding sequences of the adenovirus genome.
32. Lieber A, He CY, Kirillova I, Kay MA: Recombinant adenoviruses with large deletions generated by cre-mediated excision exhibit different biological properties compared with first- generation vectors in vitro and in vivo. J Virol 1996, 70:8944-8960. The prokaryotic Cre/lox P recombination system was adapted to generate recombinant adenovirus with extended deletions (amplicons). Using this system, the background of helper virus to amplicon was reduced to 0.5%. These amplicons were shown to have limited stability within transduced cells.
33. Hardy S, Kitamura M, Harris-Stansil T, Dai YM, Phipps ML: Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997, 71:1842-1849. A prokaryotic Cre/lox P recombination system was used, generating adenovirus vectors that lack all coding sequences of the adenovirus genome.
34. Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR: Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 1997, 94:1645-1650.
35. Ginsberg HS, Lundholm-Beauchamp U, Horswood RL, Pernis B, Wold WS, Chanock RM, Prince GA: Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc Natl Acad Sci USA 1989, 86:3823-3827.
36. Ginsberg HS, Horswood RL, Chanock RM, Prince GA: Role of early genes in pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 1990, 87:6191-6195.
37. Ginsberg HS, Moldawer LL, Sehgal PB, Redington M, Kilian PL, Chanock RM, Prince GA: A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 1991, 88:1651-1655.
38. Wilmott RW, Amin RS, Perez CR, Wert SE, Keller G, Boivin GP, Hirsch R, De Inocencio J, Lu PR, Reising SF et al.: Safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of nonhuman primates. Hum Gene Ther 1996, 7:301-318.
39. McCoy RD, Davidson BL, Roessler BJ, Huffnagle GB, Janich SL, Laing TJ, Simon RH: Pulmonary inflammation induced by incomplete or inactivated adenoviral particles. Hum Gene Ther 1995, 6:1553-1560.
40. Bruder JT, Kovesdi I: Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. J Virol 1997, 71:398-404. The authors demonstrated that early steps in the adenovirus infection process activate the Raf-1/MapK signaling pathway and induce IL-8 production.
41. Yang Y, Li Q, Ertl HCJ, Wilson JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995, 69:2004-2015.
42. Yang Y, Ertl HC, Wilson JM: MHC class I-restricted cytotoxic T lymphocytes to viral antigens. Immunity 1994, 1:433-442.
43. Yang YP, Su Q, Wilson JM: Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol 1996, 70:7209-7212.
44. Tripathy SK, Black HB, Goldwasser E, Leiden JM: Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996, 2:545-550. The authors demonstrate that under certain conditions, immune responses against foreign transgene products are the major determinants to the stability of transgene expression; and that non-immunogenic transgene expression can persist in immunocompetent animals following intramuscular delivery of adenovirus vectors.
45. Yang Y, Xiang Z, Ertl HCJ, Wilson JM: Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci USA 1995, 92:7257-7261.
46. 4+ CTLs in vivo. J Immunol 1995, 155:2564-2570.
47. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM: Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996, 3:137-144.
48. Kjellen L, Pereira HG: Role of adenovirus antigens in the induction of virus neutralizing antibody. J Gen Virol 1968, 2:177-185.
49. Wohlfart CE, Svensson UK, Everitt E: Interaction between HeLa cells and adenovirus type 2 virions neutralized by different antisera. J Virol 1985, 56:896-903.
50. Wohlfart C: Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol 1988, 62:2321-2328.
51. Horwitz MS: Adenoviridae and their replication. In Virology. Edited by Fields BN, Knipe DM, Chanocket RM, Melnick J, Roizman B, Shope R. New York: Raven Press; 1990:1679-1721.
52. Mastrangeli A, Harvey BG, Yao J, Wolff G, Kovesdi I, Crystal RG, Falck-Pedersen E: 'Sero-switch' adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 1936, 7:79-87.
53. Kass-Eisler A, Leinwand L, Gall J, Bloom B, Falck-Pedersen E: Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther 1996, 3:154-162.
54. Mack CA, Song WR, Carpenter H, Wickham TJ, Kovesdi I, Harvey BG, Magovern CJ, Isom OW, Rosengart T, Falck-Pedersen E et al.: Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997, 8:99-109.
55. Jooss K, Yang YP, Wilson JM: Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 1996, 7:1555-1566. Cyclophosphamide treatment prolonged gene expression in the liver following intravenous delivery and blocked the generation of neutralizing antibodies, permitting vector readministration following intratracheal administration.
56. Vilquin JT, Gurette B, Kinoshita I, Roy B, Goulet M, Gravel C, Roy R, Tremblay JP: FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther 1995, 6:1391-1401.
57. Yang Y, Greenough K, Wilson JM: Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther 1996, 3:412-420.
58. Lei DH, Lehmann M, Shellito JE, Nelson S, Siegling A, Volk HD, Kolls JK: Nondepleting anti-CD4 antibody treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats. Hum Gene Ther 1996, 7:2273-2279. The non-depleting anti-CD4 antibody prolonged reporter gene expression in the lung, reduced peribronchial and alveolar inflammation, and blocked the generation of neutralizing antibodies, allowing for effective repeat administration.
59. Kolls JK, Lei DH, Odom G, Nelson S, Summer WR, Gerber MA, Shellito JE: Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum Gene Ther 1996, 7:489-497.
60. Kay MA, Holterman AX, Meuse L, Gown A, Ochs HD, Linsley PS, Wilson CB: Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4lg administration. Nat Gene 1995, 11:191-197.
61. Yang YP, Su Q, Grewal IS, Schilz R, Flavell RA, Wilson JM: Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol 1996, 70:6370-6377. Using mice genetically deficient in CD40 ligand, this study demonstrates that adenovirus transgene expression was stabilized and adenovirus-specific neutralizing antibodies failed to develop, permitting efficient repeat administration. Anti-CD40 ligand antibody administered at the time of adenovirus delivery resulted in stabilized transgene expression and diminished production of adenovirus-specific neutralizing antibodies, allowing repeat administration.
62. Yang YP, Wilson JM: CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 1996, 273:1862-1864. Using mice genetically deficient in CD40 ligand, this study demonstrated that CD40 ligand-dependent activation of T cells occurs through signaling of CD40 in the antigen-presenting cell to enhance requisite costimulatory pathways that include B7.
63. Kay MA, Meuse L, Gown AM, Linsley P, Hollenbaugh D, Aruffo A, Ochs HD, Wilson CB: Transient immunomodulation with anti-CD40 ligand antibody and CTLA4lg enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci USA 1997, 94:4686-4691. Anti-CD40 ligand monoclonal antibody (MR-1) was somewhat less effective than CTLA4lg in prolonging transgene expression (hAAT). The combination resulted in persistent expression and blocked the humoral response, allowing for successful secondary adenovirus vector administration.
64. Ilan Y, Droguett G, Chowdhury NR, Li YA, Sengupta K, Thummala NR, Davidson A, Chowdhury JR, Horwitz MS: Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA 1997, 94:2587-2592. The authors demonstrate that expression of the adenovirus E3 products from an adenovirus vector reduced the humoral immune response and allowed for successful repeat administration.
65. Wickham TJ, Mathias DA, Cheresh DA, Nemerow GR: Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment. Cell 1993, 73:309-319.
66. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275:1320-1323. The authors describe the discovery of the receptor that mediates adenovirus attachment to host cells. Transduction of cells lacking the receptor led to large increases in virus binding and in transduction by adenovirus. Identification of the receptor has important implications for therapeutic gene delivery with adenovirus vectors.
67. Tomko RP, Xu RL, Philipson L: HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997, 94:3352-3356. This paper describes the co-discovery of the human and mouse forms of the adenovirus fiber receptor, called the coxsackievirus-adenovirus receptor (CAR); this is the same receptor identified by Bergelson et al. 1997. The authors show the tissue distribution of the receptor in mice, which is useful for understanding the tissue tropism of adenovirus as well as the relative susceptibilities of different tissues to transduction by adenovirus.
68. Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA: Adenovirus type 5 fiber knob binds to MHC class I α2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J 1997, 16:2294-2306. Screening of a phage display peptide library for binding to the adenovirus fiber led to the discovery of fiber-binding peptides with limited homology to the MHC class I α2 domain. Increased binding of adenovirus to cells expressing MHC class I suggested that the adenovirus fiber utilizes MHC class I as a receptor.
69. Gall J, Kass-Eisler A, Leinwand L, Falck-Pedersen E: Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 1996, 70:2116-2123.
70. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT: Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996, 70:6839-6846. The authors describe a novel method of generating recombinant adenovirus vectors with modified fibers. They show the utility of the system by generating an adenovirus containing a chimeric fiber protein comprised of a serotype 3 knob fused to the serotype 5 fiber shaft.
71. Stevenson SC, Rollence M, White B, Weaver L, McClelland A: Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol 1995, 69:2850-2857.
72. Roelvink PW, Kovesdi I, Wickham TJ: Comparative analysis of adenovirus fiber-cell interaction: adenovirus type 2 (Ad2) and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment. J Virol 1996, 70:7614-7621. The adenovirus serotype 9 fiber, while recognizing the same receptor as the adenovirus serotype 5 fiber, has a much shorter fiber shaft, which permits the virus to bind directly to cells via its penton base.
73. Wickham TJ, Carrion ME, Kovesdi I: Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther 1995, 10:750-756.
74. Michael SI, Hong JS, Curiel DT, Engler JA: Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther 1995, 2:660-668.
75. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I: Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol 1996, 14:1570-1573. This paper describes a very promising new adenovirus vector incorporating a heparin binding domain into its fiber which targets the virus to broadly expressed, heparan-containing cellular receptors. The transduction efficiency of cells not easily infected by adenovirus can be increased by as much as two logs in many cases using this vector.
76. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
77. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA: Integrin distribution in malignant melanoma: association of the β3 subunit with tumor progression. Cancer Res 1990, 50:6757-6764.
78. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng MZ, Curiel DT: Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996, 14:1574-1578. An elegant design of a truly targeted adenovirus system by utilizing a single-chain antibody which neutralizes fiber binding. Folate molecules were chemically conjugated to a single-chain antibody which blocks adenovirus binding to its native receptor. this bispecific molecule was then able to redirect adenovirus binding to folate receptors which are over-expressed on certain tumor cells while avoiding transduction of cells expressing the native receptor.
79. Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM, Kovesdi I: Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996, 70:6831-6838. The authors demonstrate that bispecific antibodies can be successfully used to target adenovirus to a specific cellular receptor and thereby increase the efficiency of gene transfer.
80. Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Ying WB, Siegal GP, Baird A, Campain JA, Curiel DT: Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 1997, 57:1447-1451.